PSI-938: Preliminary Phase I data

Preliminary data from a U.S. Phase I trial in 40 patients with chronic HCV genotype 1 infection showed that once-daily 100, 200 and 300 mg oral PSI-938 and twice-daily 100 mg PSI-938 for 7 days reduce...